Detalles de la búsqueda
1.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493791
2.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36495881
3.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37696588
4.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.
RMD Open
; 10(1)2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38388171
5.
Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study.
Arthritis Rheumatol
; 74(12): 1959-1970, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35829656
6.
Prevention of acute mountain sickness by acetazolamide in Nepali porters: a double-blind controlled trial.
Wilderness Environ Med
; 17(2): 87-93, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-16805144
7.
Trekkers' awareness of acute mountain sickness and acetazolamide.
Wilderness Environ Med
; 19(4): 321-2, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-19099325
Resultados
1 -
7
de 7
1
Próxima >
>>